CoChat

A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma

Dutton-Regester, Ken, Irwin, Darryl, Hunt, Priscilla, Aoude, Lauren G., Tembe, Varsha, Pupo, Gulietta M., Lanagan, Cathy, Carter, Candace D., O'Connor, Linda, O'Rourke, Michael, Scolyer, Richard A., Mann, Graham J., Schmidt, Christopher W., Herington, Adrian, Hayward, Nicholas K. · 2012 · Molecular Cancer Therapeutics
Cited by 49

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Success with molecular-based targeted drugs in the treatment of cancer has ignited extensive research efforts within the field of personalized therapeutics. However, successful application of such therapies is dependent on the presence or absence of mutations within the patient's tumor that can confer clinical efficacy or drug resistance. Building on these findings, we developed a high-throughput mutation panel for the identification of frequently occurring and clinically relevant mutations in melanoma. An extensive literature search and interrogation of the Catalogue of Somatic Mutations in Cancer database identified more than 1,000 melanoma mutations. Applying a filtering strategy to focus on mutations amenable to the development of targeted drugs, we initially screened 120 known mutations in 271 samples using the Sequenom MassARRAY system. A total of 252 mutations were detected in 17 genes, the highest frequency occurred in BRAF (n = 154, 57%), NRAS (n = 55, 20%), CDK4 (n = 8, 3%), PTK2B (n = 7, 2.5%), and ERBB4 (n = 5, 2%). Based on this initial discovery screen, a total of 46 assays interrogating 39 mutations in 20 genes were designed to develop a melanoma-specific panel. These assays were distributed in multiplexes over 8 wells using strict assay design parameters optimized for sensitive mutation detection. The final melanoma-specific mutation panel is a cost effective, sensitive, high-throughput approach for identifying mutations of clinical relevance to molecular-based therapeutics for the treatment of melanoma. When used in a clinical research setting, the panel may rapidly and accurately identify potentially effective treatment strategies using novel or existing molecularly targeted drugs. Mol Cancer Ther; 11(4); 888–97. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-11-0676

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 49

Metadata

Authors
Dutton-Regester, K., Irwin, D., Hunt, P., Aoude, L. G., Tembe, V., Pupo, G. M., Lanagan, C., Carter, C. D., O'Connor, L., O'Rourke, M., Scolyer, R. A., Mann, G. J., Schmidt, C. W., Herington, A., & Hayward, N. K.
Venue
Molecular Cancer Therapeutics
Published
2012-04-01
Volume
11
Issue
4
Pages
888-897
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W1548446964
Cited by
49
References
5
FWCI
3.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. https://app.cochat.ai/papers/10.1158/1535-7163.mct-11-0676
The paper
Dutton-Regester, K., Irwin, D., Hunt, P., Aoude, L. G., Tembe, V., Pupo, G. M., Lanagan, C., Carter, C. D., O'Connor, L., O'Rourke, M., Scolyer, R. A., Mann, G. J., Schmidt, C. W., Herington, A., & Hayward, N. K. (2012). A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-11-0676

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.